GRAMMER Aktiengesellschaft

  • WKN: 589540
  • ISIN: DE0005895403
  • Land: Deutschland


Name Informationen
Alfred Weber (Aufsichtsratvorsitzender) Lebenslauf
Horst Ott Lebenslauf
Andrea Elsner Lebenslauf
Antje Wagner Lebenslauf
Dr.-Ing. Ping He Lebenslauf
Martin Heiss Lebenslauf
Gabriele Sons Lebenslauf
Klaus Bauer Lebenslauf
Prof. Dr. Ing. Birgit Vogel-Heuser Lebenslauf
Dr. Peter Merten Lebenslauf
Peter Kern Lebenslauf
Dipl.-Ing. Jürgen Kostanjevec Lebenslauf

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Neufassung der Dividendenpolitik der Allianz SE

02. Dezember 2021, 20:33

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021